The impact of extended half‐life factor concentrates on prophylaxis for severe hemophilia in the United StatesLynn Malec, Margaret V. Ragni, Michael Recht et al.|American Journal of Hematology|2020Cited by 31
rFIXFc for Immune Tolerance Induction in a Severe Hemophilia B Patient with an Inhibitor and Prior History of ITI Related Nephrotic SyndromeLynn Malec, Gilbert White, Thomas C. Abshire et al.|Haemophilia|2018Cited by 8
Adoption of Prophylaxis in the United States in the Era of Extended Half-Life Factor ConcentratesLynn Malec, Margaret V. Ragni, Stacy E. Croteau et al.|Blood|2018Cited by 2
Real World Use of Extended Half-Life Products and the Impact on Bleeding Events and Joint Health in the United StatesLynn Malec, Margaret V. Ragni, Char Witmer et al.|Blood|2018Cited by 2